Annual report pursuant to Section 13 and 15(d)

License Agreements (Details Textual)

v3.8.0.1
License Agreements (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
May 31, 2016
Sep. 30, 2015
May 31, 2015
Mar. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Clinical Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         $ 87,200,000    
Neupharma [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Payment Of Upfront Fees       $ 1,000,000      
Reimbursement Of Cost Recognized As Revenue         600,000 $ 1,000,000  
Payment For Non refundable Milestone payments           1,000,000  
Neupharma [Member] | Additional Sales Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         22,500,000    
Neupharma [Member] | Clinical Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         40,000,000    
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         40,000,000    
Dana-Farber [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Shares Issued, Price Per Share     $ 0.065        
Stock Issued During Period, Shares, Issued for Services   136,830 500,000        
Stock Issued During Period, Value, Issued for Services   $ 600,000 $ 32,500        
Payment Of Upfront Fees       $ 1,000,000      
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners     5.00%        
Proceeds from Issuance of Common Stock   $ 10,000,000          
Dana-Farber [Member] | First Commercial Sale Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         21,500,000    
Maximum Potential Milestone Payments         21,500,000    
Dana-Farber [Member] | Additional Sales Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         60,000,000    
Maximum Potential Milestone Payments         60,000,000    
Teva Pharmaceutical Industries Ltd [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Payment Of Upfront Fees         500,000    
Teva Pharmaceutical Industries Ltd [Member] | Clinical Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         220,000,000    
Teva Pharmaceutical Industries Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         206,500,000    
Jubilant Biosys Ltd [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Payment Of Upfront Fees $ 2,000,000            
Revenue Recognition, Milestone Method, Revenue Recognized         1,000,000 1,500,000  
Research and Development Cost, Shared Percentage 50.00%            
Jubilant Biosys Ltd [Member] | Clinical Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         89,000,000    
Maximum Potential Milestone Payments         89,000,000    
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         59,500,000    
Jubilant Biosys Ltd [Member] | Successful Achievement Of One Preclinical Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         25,500,000    
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         61,700,000    
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Maximum Potential Milestone Payments         89,000,000    
Collaboration Agreement With TGTX [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Payment Of Upfront Fees $ 1,000,000            
Revenue Recognition, Milestone Method, Revenue Recognized         84,000 $ 42,000 $ 590,000
Payment Of Upfront Licensing Fee         500,000    
Collaboration Agreement With TGTX [Member] | Clinical Development Milestone [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         7,000,000    
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member]              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Revenue Recognition Milestone Method, Payments Due         $ 14,500,000